Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VERTEX PHARMACEUTICALS

(VRTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Vertex Pharmaceuticals : Morgan Stanley Adjusts Vertex Pharmaceuticals' Price Target to $202 From $205, Keeps Equal-Weight Rating

07/30/2021 | 11:55am EDT


© MT Newswires 2021
All news about VERTEX PHARMACEUTICALS
01:55pVERTEX PHARMACEUTICALS' : Kalydeco Drug Submission Accepted for Priority Review by Health ..
MT
11:17aVERTEX PHARMACEUTICALS : Supplement to a New Drug Submission for KALYDECO® (ivacaftor) for..
AQ
09/17VERTEX PHARMACEUTICALS : Announces Letter of Intent With pan-Canadian Pharmaceutical Allia..
AQ
09/17Vertex Pharmaceuticals Incorporated Letter of Intent with Pan-Canadian Pharmaceutical A..
CI
09/15Vertex Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2021
CI
09/14VERTEX PHARMACEUTICALS : to Present at the Morgan Stanley Virtual 19th Annual Global Healt..
AQ
09/13VERTEX PHARMACEUTICALS : to Present at the Morgan Stanley Virtual 19th Annual Global Healt..
BU
09/10NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/09WALL STREET STOCK EXCHANGE : A step closer to tapering
09/09VERTEX PHARMACEUTICALS : Stifel Downgrades Vertex Pharmaceuticals to Hold from Buy, Adjust..
MT
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 7 269 M - -
Net income 2021 2 082 M - -
Net cash 2021 8 091 M - -
P/E ratio 2021 23,0x
Yield 2021 -
Capitalization 47 805 M 47 805 M -
EV / Sales 2021 5,46x
EV / Sales 2022 4,51x
Nbr of Employees 3 400
Free-Float 99,9%
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | MarketScreener
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 184,27 $
Average target price 260,91 $
Spread / Average Target 41,6%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS-22.03%48 202
GILEAD SCIENCES, INC.23.12%89 936
BIONTECH SE318.73%82 443
WUXI APPTEC CO., LTD.36.63%69 407
REGENERON PHARMACEUTICALS33.91%67 262
BEIGENE, LTD.50.36%36 146